BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $ACAD readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07284667-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~NORLIGHT readout (P2) · ACADIA Pharmaceuticals Inc. $ACAD
DESCRIPTION:ACP-211 Monotherapy for Major Depressive Disorder With Inadequa
 te Antidepressant Response\n\nPrimary completion date: 2027-08 (estimated)
  — month only\, shown on the 1st\nPhase 2 · Neuro · Major Depressive D
 isorder (MDD)\, Depressive Disorder\, Treatment-Resistant\nEnrollment: 153
  · Sites: 28\n\nPrimary completion = last participant's primary-endpoint 
 data collected\; topline results usually follow weeks to months later. Spo
 nsor-reported\, often an estimate. Not investment advice.\n\nhttps://datac
 utoff.com/radar.html?nct=NCT07284667\nhttps://clinicaltrials.gov/study/NCT
 07284667
URL:https://datacutoff.com/radar.html?nct=NCT07284667
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
